Combination Therapy to Outsmart RASAddicted Cancer – Informing Clinical Strategy with Preclinical Modeling

Time: 11:45 am
day: Translation Track - Day 1 am


  • Identify biomarkers that can help direct the “right combination regimen” to the “right patients”
  • Define upfront combination regimens that can prevent/ delay emergent resistance mechanisms to RevMed RAS(ON) inhibitors
  • Understand if/how we can translate learnings between distinct RAS mutations and cancer histotypes